- Home
- TS vs RPRX Comparison
TS vs RPRX Comparison
Compare TS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TS | RPRX |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TS | RPRX |
|---|---|---|
| Price | $40.86 | $39.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $42.60 | ★ $46.00 |
| AVG Volume (30 Days) | 963.0K | ★ 4.3M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.16% | 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.86 | 1.75 |
| Revenue | ★ $11,831,250,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.13 |
| Revenue Next Year | $0.77 | $1.48 |
| P/E Ratio | ★ $10.57 | $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $30.06 | $24.05 |
| 52 Week High | $41.76 | $41.24 |
Technical Indicators
Market Signals| Indicator | TS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 57.50 |
| Support Level | $39.38 | $39.24 |
| Resistance Level | $41.59 | $40.50 |
| Average True Range (ATR) | 0.69 | 0.91 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 72.37 | 76.02 |
Price Performance
Historical ComparisonAbout TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.